Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - sildenafil citrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: macrogol 8000; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; hypromellose; titanium dioxide; hyprolose - sildenafil is used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil has not been evaluated in patients currently on bosentan therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sildenafil citrate, quantity: 35.1 mg (equivalent: sildenafil, qty 25 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; magnesium stearate; copovidone; microcrystalline cellulose; saccharin sodium; calcium hydrogen phosphate; croscarmellose sodium - sildenafil sandoz is indicated for the treatment of erectile dysfunction in adult males. sildenafil sandoz is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sildenafil citrate, quantity: 140.4 mg (equivalent: sildenafil, qty 100 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; copovidone; croscarmellose sodium; saccharin sodium; indigo carmine aluminium lake; calcium hydrogen phosphate; magnesium stearate - sildenafil sandoz is indicated for the treatment of erectile dysfunction in adult males. sildenafil sandoz is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sildenafil citrate, quantity: 70.2 mg (equivalent: sildenafil, qty 50 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate; magnesium stearate; copovidone; saccharin sodium - sildenafil sandoz is indicated for the treatment of erectile dysfunction in adult males. sildenafil sandoz is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sildenafil citrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sildenafil citrate -

United States - English - NLM (National Library of Medicine)

greenstone llc - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil 25 mg - sildenafil citrate tablets is indicated for the treatment of erectile dysfunction. consistent with its known effects on the nitric oxide/cgmp pathway [see clinical pharmacology (12.1, 12.2) ], sildenafil citrate tablets were shown to potentiate the hypotensive effects of nitrates, and their administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated. after patients have taken sildenafil citrate tablets, it is unknown when nitrates, if necessary, can be safely administered. although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [see dosage and administration (2.3), drug interactions (7.1), and clinical pharmacology (12.2) ]. sildenafil citrate tablets are contraindicated in patients with a known hypersensitivity to sildenafil, as contained in sildenafil citrate

United States - English - NLM (National Library of Medicine)

vensun pharmaceuticals, inc. - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil 20 mg - sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (who group i) in adults to improve exercise ability and delay clinical worsening. the delay in clinical worsening was demonstrated when sildenafil tablets were added to background epoprostenol therapy [see clinical studies (14)]. studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with new york heart association (nyha) functional class ii-iii symptoms and idiopathic etiology (71%) or associated with connective tissue disease (ctd) (25%). limitation of use : adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity [see clinical studies (14)]. sildenafil tablets are contraindicated in patients with: -   concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see warnings and precautions (5.2)]. -   concomitant use of riociguat, a guanylate cyclase stimulator.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate -